Hibiscus Sabdariffa and Centella Asiatica in the Treatment of Anemia by Iron Deficiency
Sponsor
Casa Espirita Terra de Ismael (Other)
Overall Status
Completed
CT.gov ID
NCT01414374
Collaborator
University of Sao Paulo (Other)
50
1
2
14
3.6
Study Details
Study Description
Brief Summary
The study aims to investigate the prevalence of genetic polymorphisms in adults with iron deficiency and anemia, and the responses to two different treatments: iron sulphate and a composite herbal medicine (Hibiscus sabdariffa plus Centella asiatica). The main outcome will be hemoglobin, measured before and after 6 weeks.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Study Design
Study Type:
Interventional
Actual Enrollment
:
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Prevalence of Genetic Polymorphisms of DMT1 and Ferroportin Enzymes in Adults With Anemia by Iron Deficiency, and Its Influence on the Efficacy of Conventional and Herbal Treatments
Study Start Date
:
Jan 1, 2012
Actual Primary Completion Date
:
Dec 1, 2012
Actual Study Completion Date
:
Mar 1, 2013
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: Iron
|
Drug: Iron
Patients will receive iron sulphate, 500 mg, BID, plus orange juice, for 6 weeks.
|
Experimental: Herbal
|
Drug: Herbal medicine
Patients will receive a combination of Hibiscus sabdariffa (powdered dry plant), 200 mg, BID, and Centella asiatica tincture, 40 drops, BID, for 6 weeks.
|
Outcome Measures
Primary Outcome Measures
- Hemoglobin [6 weeks]
Hemoglobin will be measured before treatment and after 6 weeks of treatment
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Age > 18 y and < 50 y
-
A diagnostic of iron deficient anemia
Exclusion Criteria:
-
Severe anemia
-
Treatment interruption for more than 25% of the 6 weeks
-
New onset severe adverse symptoms or events
-
Patient's request
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Laboratorio M. F. Teixeira | Monte Santo de Minas | Minas Gerais | Brazil |
Sponsors and Collaborators
- Casa Espirita Terra de Ismael
- University of Sao Paulo
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Fabio Carmona,
Assistant Professor,
University of Sao Paulo
ClinicalTrials.gov Identifier:
NCT01414374
Other Study ID Numbers:
- ANEMIA2011
First Posted:
Aug 11, 2011
Last Update Posted:
Feb 13, 2015
Last Verified:
Feb 1, 2015
Keywords provided by Fabio Carmona,
Assistant Professor,
University of Sao Paulo
Additional relevant MeSH terms: